Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

02-27

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45^th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.

A live webcast of the fireside chat will be available to conference participants on March 4^th at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications, kfox@milestonepharma.com

Investor Relations

Chris Calabrese, ccalabrese@lifesciadvisors.com

Kevin Gardner, kgardner@lifesciadvisors.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514046708"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514046708\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514046708?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514046708","market":"hk","top_or_hot":-1,"title":"Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference","media":"GlobeNewswire","content":"<html><body><p>MONTREAL and CHARLOTTE, N.C., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Milestone<sup>®</sup> Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45<sup>th</sup> Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.</p> <p>A live webcast of the fireside chat will be available to conference participants on March 4<sup>th</sup> at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News &amp; Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.</p> <p><strong>About Milestone Pharmaceuticals</strong></p> <p><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a> (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.</p> <p><strong>Contact:</strong></p> <p>Kim Fox, Vice President, Communications<strong>, </strong>kfox@milestonepharma.com</p> <p><strong>Investor Relations</strong></p> <p>Chris Calabrese, ccalabrese@lifesciadvisors.com</p> <p>Kevin Gardner, kgardner@lifesciadvisors.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/YmI2NjJkZGMtYTczNC00ZmVkLWE1MzgtYjJkNDkxNDk2MWIzLTUwMDEyMTAzNg==/tiny/Milestone-Pharmaceuticals-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMilestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-02-27 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>MONTREAL and CHARLOTTE, N.C., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Milestone<sup>®</sup> Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45<sup>th</sup> Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.</p> <p>A live webcast of the fireside chat will be available to conference participants on March 4<sup>th</sup> at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News &amp; Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.</p> <p><strong>About Milestone Pharmaceuticals</strong></p> <p><a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a> (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.</p> <p><strong>Contact:</strong></p> <p>Kim Fox, Vice President, Communications<strong>, </strong>kfox@milestonepharma.com</p> <p><strong>Investor Relations</strong></p> <p>Chris Calabrese, ccalabrese@lifesciadvisors.com</p> <p>Kevin Gardner, kgardner@lifesciadvisors.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/YmI2NjJkZGMtYTczNC00ZmVkLWE1MzgtYjJkNDkxNDk2MWIzLTUwMDEyMTAzNg==/tiny/Milestone-Pharmaceuticals-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4207","symbol_name":"综合性银行","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033810/0/en/Milestone-Pharmaceuticals-to-Present-at-the-TD-Cowen-45th-Annual-Health-Care-Conference.html","article_id":"2514046708","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514046708","pubTimestamp":1740661200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"MONTREAL and CHARLOTTE, N.C., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc.(Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th An","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4207":"综合性银行","TD":"道明银行","BK4127":"投资银行业与经纪业","BK4585":"ETF&股票定投概念","BK4566":"资本集团","COWN":"高宏集团"},"translate_title":"里程碑®制药公司将出席TD Cowen第45届年度医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COWN":1,"TD":1},"content_text":"MONTREAL and CHARLOTTE, N.C., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston. A live webcast of the fireside chat will be available to conference participants on March 4th at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR. Contact: Kim Fox, Vice President, Communications, kfox@milestonepharma.com Investor Relations Chris Calabrese, ccalabrese@lifesciadvisors.com Kevin Gardner, kgardner@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}